Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 217 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR New ESMO President 2029-2030 Elected June 3, 2026 Consensus on Conceptual Framework for Precision Cancer Medicine in Germany July 20, 2020 Helping Kids with Cancer Speak for the Supportive Care They Need December 13, 2024 Survivorship and Immune Checkpoint Inhibitors July 21, 2020 Load more HOT NEWS GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active...
